SC
CNTA

Stempoint Capital’s Centessa Pharmaceuticals CNTA Stock Holding History

Stempoint Capital’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,000
Closed -$26.3K – 92
2025
Q4 		$26.3K Sell
75,000
-97,500
-57% -$2.47M ﹤0.01% 77
2025
Q3 		$906K Buy
+172,500
New +$3.07M 0.18% 65

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Stempoint Capital's CNTA Position: Q1 2026 in Review

Stempoint Capital sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 1,154,114 shares — an estimated $28.9M sold.

Stempoint Capital first reported a position in CNTA in Q3 2024 and held it in 6 quarters. The position peaked at $28.9M in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Stempoint Capital reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 1,154,114 Centessa Pharmaceuticals shares in Q1 2026, an estimated $28.9M.
  • Stempoint Capital first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Stempoint Capital's Centessa Pharmaceuticals position peaked at $28.9M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.